Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 22

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 22
---
 or
by a supplement to this prospectus) and (ii) any donees, pledgees, transferees or other successors-in-interest that acquire
any of the securities covered by this prospectus after the date of this prospectus from the named Selling Shareholders as a gift, pledge,
partnership distribution or other non-sale related transfer.

The
table below sets forth, as of the date of this prospectus, the names of the Selling Shareholders for which we are registering ordinary
shares for resale to the public, and the aggregate principal amount that the Selling Shareholders may offer pursuant to this prospectus.
In accordance with SEC rules, individuals and entities below are shown as having beneficial ownership over shares they own or have the
right to acquire within 60 days, as well as shares for which they have the right to vote or dispose of such shares.

The
percentage of ordinary shares beneficially owned after the offering is based on 84,819,996 ordinary shares outstanding as of June 20,
2025, and for Oramed gives effect to the exercise in full of the IR/PR Warrants. The foregoing number of shares outstanding does not give
effect to the issuance of ordinary shares to A & M Construction pursuant to the Design-Build Agreement amendment. Also in accordance
with SEC rules, for purposes of calculating percentages of beneficial ownership, shares which a person has the right to acquire within
60 days of June 20, 2025 are included both in that person’s beneficial ownership as well as in the total number of ordinary
shares issued and outstanding used to calculate that person’s percentage ownership but not for purposes of calculating the percentage
for other persons. In some cases, the same ordinary shares are reflected more than once in the table below because more than one holder
may be deemed the beneficial owner of the same ordinary shares.

We
cannot advise you as to whether the Selling Shareholders will in fact sell any or all of such securities. In addition, the Selling Shareholders
may sell, transfer or otherwise dispose of, at any time and from time to time, the ordinary shares in transactions exempt from the registration
requirements of the Securities Act after the date of this prospectus, subject to applicable law.

Selling
Shareholder information for each additional Selling Shareholder, if any, will be set forth by prospectus supplement to the extent required
prior to the time of any offer or sale of such Selling Shareholder’s securities pursuant to this prospectus. Any prospectus supplement
may add,